FDA Grants Accelerated Approval to Selpercatinib for Pediatric Patients Aged 2 and Older With RET-Altered Metastatic Thyroid Cancer or Solid Tumors
On May 29, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo®) for pediatric patients aged 2 and older.This is the first FDA approval of a targeted therapy for pediatric patients younger than 12 withRETalterations.